

Original Articles:

1. Löw I, Friedrich T, Burckhardt G:
Properties of an anion exchanger in rat renal basolateral membrane vesicles
Am J. Physiol. 246: F334-F342, 1984
2. Löw I, Friedrich T, Schoeppe W:
Synthesis of shock proteins in cultured fetal mouse myocardial cells
Exp. Cell Res. 180: 451-459, 1989
3. Löw I, Grützmacher P, Bergmann M, Schoeppe W:
Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin
Clin. Nephrol. 31 (1): 26-30, 1989
4. Löw-Friedrich I, Ühlein M, Mondorf U, Ernst W, Schoeppe W:
Studies of an in vitro assay for myocardial allograft rejection
Transpl. Proc. 22 (4): 1838-1843, 1990
5. Löw-Friedrich I, von Bredow F, Schoeppe W:
In vitro studies on the cardiotoxicity of chemotherapeutics
Chemotherapy 36: 416-421, 1990
6. Löw-Friedrich I, Grützmacher P, März W, Bergmann M, Schoeppe W:
Longterm echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin
Blood Purif. 8: 272-278, 1990
7. Löw-Friedrich I, von Bredow F, Schoeppe W:
A cell culture assay for the detection of cardiotoxicity
J. Pharmacol. Methods 25: 133-145, 1991
8. Löw-Friedrich I, Grützmacher P, März W, Bergmann M, Schoeppe W:
Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients
Am. J. Nephrol. 11: 54-60, 1991
9. Löw-Friedrich I, Schoeppe W:
Effects of calcium channel blockers on stress protein synthesis in cardiac myocytes
J. Cardiovasc. Pharmacol. 17: 800-806, 1991
10. Löw-Friedrich I, Weisensee D, Mitrou P, Schoeppe W:
Cytokines induce stress protein formation in cultured cardiac myocytes
Basic Res. Cardiol. 87: 12-18, 1992
11. Löw-Friedrich I, Grützmacher P, Bergmann M, Schoeppe W:
Echokardiographische Untersuchungen an polytransfunden chronisch hämodialysepflichtigen Patienten unter Substitution mit rekombinantem humanem Erythropoietin
Med. Welt 43: 423-425, 1992
12. Grützmacher P, Bergmann M, Löw-Friedrich I, Rauber K, Baum R, Schoeppe W:
Kardiale Veränderungen unter Langzeittherapie der renalen Anämie mit rekombinantem humanem Erythropoietin
Nieren- und Hochdruckkrankheiten 19 (5): 192-198, 1990
13. Löw-Friedrich I:
Cardiac improvement in a long term haemodialysis patient under substitution with r-HuEPO
Erythropoiesis 2 (2): 56, 1991

14. Stahl R, Löw I, Schoeppe W:
Progressive renal failure in a patient after one and two-thirds nephrectomy
Klin. Wo. 66: 508-510, 1988
15. Weisensee D, Bereiter-Hahn J, Schoeppe W, Löw-Friedrich I:
Effects of cytokines on the contractility of cultured cardiac myocytes
Int. J. Immunopharmac. 15 (5): 581-587, 1993
16. Weisensee D, Löw-Friedrich I, Riehle M, Bereiter-Hahn J, Schoeppe W:
In vitro approach to "uremic cardiomyopathy"
Nephron 65: 392-400, 1993
17. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, Campion G, Musikic P, Löw-Friedrich I, Oed Ch, Seifert H, Strand V:
Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. – Results of a randomized, placebo-controlled, phase II study
Arthritis and Rheumatism 38 (11): 1595-1603, 1995
18. Weisensee D, Seeger T, Bittner A, Bereiter-Hahn J, Schoeppe W, Löw-Friedrich I:
Cocultures of fetal and adult cardiomyocytes yield rhythmically beating rod shaped heart cells from adult rats
In Vitro Cell. Dev. Biol. 31: 190-195, 1995
19. Sharma H S, Stahl J, Weisensee D, Löw-Friedrich I:
Cytoprotective mechanisms in cultured cardiomyocytes
Mol. Cell. Biochem. 160/161: 217-224, 1996
20. Sharma H S, Weisensee D, Löw-Friedrich I:
Tumor necrosis factor-alpha-induced cytoprotective mechanisms in cardiomyocytes. Analysis by mRNA phenotyping
Annals New York Academy of Sciences 793: 267-281, 1996
21. Weisensee D, Schnaars Y, Schoeppe W, Bereiter-Hahn J, Löw-Friedrich I:
Potential uremic toxins modulate energy metabolism of cardiac myocytes in vitro
Exp. Nephrol. 5: 194-200, 1997
22. Smolen J S, Kalden J R, Scott D L, Rozman B, Kvien T K, Larsen A, Löw-Friedrich I, Oed Ch, Rosenberg R, and the European Leflunomide Study Group:
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial
The Lancet 353: 259-266, 1999
23. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Sharp J, Löw-Friedrich I:
Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate
Arch. Int. Med., accepted for publication in November, 1999

Published Lectures

1. Löw I:
Sulfate/anion exchange and Na⁺ dependent sulfate uptake by rat renal basolateral membrane vesicles
Naunyn-Schmiedeberg's Arch. Pharmacol. 322: R12: 1983
Vortrag bei der "Gemeinsamen Frühjahrstagung der Deutschen Pharmakologischen Gesellschaft und der Deutschen Physiologischen Gesellschaft" vom 14.-18. 03.1983 in Mainz
2. Löw I, Burckhardt G:
PAH uptake into rat renal basolateral membrane vesicles by anion exchange
Pflügers Arch. 400: R18: 1984
Vortrag bei der "59. Tagung der Deutschen Physiologischen Gesellschaft" vom 26.-30.03.1984 in Dortmund
3. Löw I, Friedrich T, Schoeppe W:
Uremic myocardiopathy: protein synthesis in cultured myocytes exposed to uremia and possible uremic toxins
Pflügers Arch. 408: R41: 1987
Vortrag bei der "64. Tagung der Deutschen Physiologischen Gesellschaft" vom 18.-21.03.1987 in Homburg/Saar
4. Löw I, Bergmann M, Grützmaker P, Schoeppe W:
Verbesserung der Herzfunktion bei chronisch dialysepflichtigen Patienten unter Erythropoietin (rhEPO)-Substitution
Kli. Wo. 66 (XIII): 190-191: 1988
Vortrag bei der "94. Tagung der Deutschen Gesellschaft für Innere Medizin" vom 10.-14.04.1988 in Wiesbaden
5. Löw-Friedrich I, Friedrich T, Schoeppe W:
Development of an in vitro model system for cardiotoxicity
Naunyn Schmiedeberg's Arch. Pharmacol. 339: R20: 1989
Vortrag bei der "30. Frühjahrstagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie" vom 14.-17.03.1989 in Mainz
6. Löw-Friedrich I, Friedrich T, Kaltenbach M, Schoeppe W:
Entwicklung eines in vitro-Kardiotoxizitäts-Modells
Z. Kardiol. 78 (1): 38: 1989
Vortrag bei der "55. Jahrestagung der Deutschen Gesellschaft für Herz- und Kreislaufforschung" vom 31.03.-02.04.1989 in Mannheim
7. Löw-Friedrich I, Grützmaker P, Bergmann M, Schoeppe W:
Echocardiographic evaluations in poly-transfused chronic hemodialysis (RDT) patients substituted with rh-erythropoietin (rhEPO)
Abstracts des 9. Donauesymposium für Nephrologie, 06.-09.09.1989 in Linz: 22: 1989
Vortrag beim "9. Donauesymposium für Nephrologie" vom 06.-09.09.1989 in Linz/Österreich
8. Löw-Friedrich I, Grützmaker P, Bergmann M, Schoeppe W:
Long-term echocardiographic examinations in chronic hemodialysis (RDT) patients substituted with recombinant human erythropoietin (rhEPO)
Blood Purif. 7 (5): 276 (72): 1989
Vortrag beim "7th Annual Meeting of the International Society of Blood Purification" vom 11.-13.09.1989 in Montpellier/Frankreich
9. Löw-Friedrich I, Ühlein M, Mondorf U, Ernst W, Schoeppe W:
Development of an in vitro assay for myocardial graft rejection (MGR)
Abstracts of the IV Congress of the European Society for Organ Transplantation 01.-04.11.1989, Barcelona: 132: 1989
Vortrag beim "IV Congress of the European Society for Organ Transplantation" vom 01.-04.11.1989 in Barcelona/Spanien

10. Löw-Friedrich I, Grützmacher P, März W, Bergmann M, Schoeppe W:
Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients
Eur. J. Clin. Invest. 20 (2): 307 (A56): 1990
Vortrag beim "24th Annual Scientific Meeting of the European Society for Clinical Investigation" vom 25.-28.04.1990 in Maastricht/Niederlande
11. Löw-Friedrich I, Schoeppe W:
Studies on the molecular mechanism of cardioprotection by calcium channel blockers
Eur. J. Pharmacol. 183 (3): 689: 1990
Vortrag beim "XIth International Congress of Pharmacology" vom 01.-06.07.1990 in Amsterdam/Niederlande
12. Löw-Friedrich I, Weisensee D, Bereiter-Hahn J, Schoeppe W:
Cultured cardiac myocytes under uremic conditions as a new approach to "uremic myocardiopathy"
In: Timio M, Wizemann V, Hrsg., Cardioneurology, Mailand, Wichtig Editore 1991, pp 367-370
Vortrag beim "Third European Meeting on Cardioneurology" vom 11.-13.04.1991 in Assisi/Italien
13. Löw-Friedrich I, Schoeppe W:
Stress proteins are possibly involved in cardioprotection by slow calcium channel blockers
Cardiovasc. Drugs Therapy 5 (3): 389 (No. 321): 1991
Vortrag beim "4th International Symposium on Cardiovascular Pharmacotherapy" vom 21.-25.04.1991 in Genf/Schweiz
14. Löw-Friedrich I, Weisensee D, Bereiter-Hahn J, Schoeppe W:
Effects of interleukins and tumor necrosis factor on stress protein synthesis and contractility of cultured cardiomyocytes
Vortrag beim Workshop "Cellular aspects of impaired heart function: sepsis versus ischemia" vom 29.-30.11.1991 in Wuppertal (Forschungszentrum der Bayer AG)
15. Löw-Friedrich I, Weisensee D, Schoeppe W:
Cardiotoxicity of cytokines
Toxicology Letters, Supplement: 99 (No. 03/08): 1992
Vortrag beim "VIth International Congress of Toxicology" vom 28.06.-03.07.1992 in Rom/Italien
16. Seifert H, Musikic P, Oed Ch, Löw-Friedrich I, Campion G:
Clinical experience on leflunomide in patients with rheumatoid arthritis (RA)
Abstract volume "Symposium Leflunomide"; congress: "Inflammation '93", Vienna, 1993
Lecture on 12 Oct. 1993 at the "Symposium Leflunomide" at the congress "Inflammation '93" from 10.-15.10.1993 in Vienna/Austria
17. Sharma H S, Weisensee D, Löw-Friedrich I, Andres J, Schaper W:
Tumor necrosis factor- α induces the expression of mRNAs encoding heat shock protein-27 and ubiquitin in cardiac myocytes
Eur. Heart J. 14: 96: 1993
Lecture at the "XVth Congress of the European Society of Cardiology" from 28.08.-02.09.1993 in Nice/France
18. Leflunomide Study Group, Campion G, Löw-Friedrich I, Oed Ch, Seifert H:
Comparison of different dosing regimens of leflunomide in the treatment of active rheumatoid arthritis (RA)
Scand. J. Rheum. Supp. 98: 140: 1994
Lecture on 03.06.1994 at the "25th Scandinavian Congress of Rheumatology" from 01.-04.06.1994 in Lillehammer/Norway
19. Seifert H, Löw-Friedrich I, Oed Ch:
Leflunomid: Ein neuer Immunmodulator für die Behandlung von chronischer Polyarthritits
Zeitschrift für Rheumatologie 53 (1): PL9: 1994
Lecture on 30.09.1994 at the "26th Congress of the German Society for Rheumatology" from 28.09.-01.10.1994 in Berlin/Germany

20. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Popovic M, Dimitrijevic M, Zivkovic M, Campion G, Musikic P, Löw-Friedrich I, Oed Ch, Seifert H, Strand V:
Phase II clinical trials with leflunomide in rheumatoid arthritis
Abstracts of the Third International Symposium on the Immunotherapy of the Rheumatic Diseases, Limassol/Zypern, Mai 1995
Lecture at the "Third International Symposium on the Immunotherapy of the Rheumatic Diseases" from 10.-14.05.1995 in Limassol/Cyprus
21. Löw-Friedrich I:
Leflunomid in der Therapie der rheumatoiden Arthritis: Aktueller Stand der klinischen Entwicklung
27th Congress of the German Society for Rheumatology, Bamberg
Symposium 7: "Immunotherapy/Immunosuppression – Future therapeutic strategies", Bamberg, September 1996
Lecture on 20.09.1996 at the Symposium No. 7:
"Immunotherapy/Immunosuppression – Future therapeutic strategies" at the "27th Congress of the German Society for Rheumatology" from 18.-21.09.1996 in Bamberg/Germany
22. Löw-Friedrich I:
Leflunomid – ein neues Basistherapeutikum zur Behandlung der rheumatoiden Arthritis
Abstracts of the 5th Rheumatology Symposium, Jena, March 1997
Lecture on 22.03.1997 at the "5th Rheumatology Symposium" in Jena/Germany
23. Smolen J S, Kalden J R, Rozman B, Scott D L, Löw-Friedrich I, Rosenberg R for the European Leflunomide Study Group:
A double-blind, randomized, phase III trial of leflunomide vs. placebo vs. sulfasalazine in rheumatoid arthritis
Arthritis and Rheumatism 41 (9): 594: 1998

Poster Presentations:

1. Löw I, Grützmaker P, Bergmann M, Schoeppe W:
Echokardiographische Langzeituntersuchungen an chronisch hämodialysepflichtigen Patienten unter rh-Erythropoietin-Substitution
Nieren- und Hochdruckkrankheiten 17 (9): 373: 1988
2. Löw I, Friedrich T, Schoeppe W:
Untersuchungen zur Kardiotoxizität von Azathioprin und Cyclosporin
Nieren- und Hochdruckkrankheiten 17 (9): 392: 1988
3. Löw I, Friedrich T, Schoeppe W:
Cyclosporine A (CsA), prednisolone and azathioprine induce the formation of a shock protein in cultured myocytes
Kidney Int. 35 (1): 506: 1989
4. Löw-Friedrich I, Grützmaker P, Bergmann M, Schoeppe W:
Einfluß von rekombinantem humanem Erythropoietin (rhEPO) auf die Herzfunktion bei Hämodialyse-Patienten
Z. Kardiol. 78 (1): P529: 1989
5. Löw-Friedrich I, Friedrich T, Schoeppe W:
Studies on an in vitro model system for cardiotoxicity
Abstracts of the V International Congress of Toxicology 16.-21.07.1989, Taylor and Francis, London: 246: 1989
6. Löw-Friedrich I, Ühlein M, Mondorf U, Ernst W, Schoeppe W:
Studies on an in vitro assay for myocardial graft rejection (MGR)
J. Mol. Cell. Cardiol. 21 (IV): P35: 1989
7. Löw-Friedrich I, Grützmaker P, März W, Bergmann M, Schoeppe W:
Die Substitution mit rekombinantem humanem Erythropoietin (rhEPO) führt zu einer Verminderung der linksventrikulären Masse und zu einer Kontraktilitätsverbesserung
Nieren- und Hochdruckkrankheiten 18 (9): 402 (144): 1989
8. Löw-Friedrich I, Ühlein M, Mondorf U, Ernst W, Kaltenbach M, Schoeppe W:
Verhalten von Myozyten-Kulturen zur Erkennung von Herztransplantat-Abstoßungen
Z. Kardiol. 78 (4): P229: 1989
9. Löw-Friedrich I, Schoeppe W:
Cardioprotection by calcium channel blockers is possibly mediated by shock proteins
J. Mol. Cell. Cardiol. 22 (III): PT 20: 1990
10. Löw-Friedrich I, Weisensee D, Bereiter-Hahn J, Schoeppe W:
A new approach to "uremic cardiomyopathy"
Abstracts of the XXVIIth Congress of the European Dialysis and Transplant Association – European Renal Association 05.-08.09.1990, Wien: 148: 1990
11. Löw-Friedrich I, Schoeppe W:
Heat shock protein synthesis in cultured cardiac myocytes
International Institute of Genetics and Biophysics, Naples/Italy
Conferences and Workshops. 3. Heat Shock: 148-149, 1990
12. Löw-Friedrich I, Weisensee D, Mitrou P, Schoeppe W:
The synthesis of stress proteins in cultured cardiac myocytes is induced by the interleukins and tumor necrosis factor
Abstracts of the 2nd International Congress on the Immune Consequences of Trauma, Shock and Sepsis, Mechanisms and Therapeutic Approaches 06.-09.03.1991, München: 100 (P45): 1991

13. Löw-Friedrich I, Weisensee D, Mitrou P S, Bereiter-Hahn J, Schoeppe W:
Cytokines directly affect contractility and stress protein formation of cardiac myocytes
Onkologie 15 (1): 28 (P-21): 1992
Ausgezeichnet mit dem "AIO-Poster-Award 1992" der Arbeitsgemeinschaft für Internistische
Onkologie anlässlich des "2nd Frankfurt International Cytokine Symposium" vom 25.-27.06.1992 in
Frankfurt am Main
14. Grützmaker P, Bergmann M, Löw I, Schoeppe W:
Cardiac changes in hemodialysis patients treated by recombinant human erythropoietin (rhEPO)
Blood Purif. 6: 357-358:1988
15. von Bredow F, Löw-Friedrich I, Schoeppe W:
Untersuchungen zur molekularen Kardiotoxizität von Zytostatika
Kli. Wo. 68 (XIX): 672: 1990
16. Weisensee D, Löw-Friedrich I, Schoeppe W, Bereiter-Hahn J:
Cultured heart cells under uremic conditions – a model for "uremic cardiomyopathy"?
Eur. J. Cell Biol. 54 (32): 216: 1991
17. Weisensee D, Löw-Friedrich I, Schoeppe W, Bereiter-Hahn J:
Effect of uremic compounds on cultured myocytes as a model for "uremic cardiomyopathy"
Zentralblatt Haut- und Geschlechtskrankheiten 158 (10): Beilage Nr. 15: 1991
18. Weisensee D, Löw-Friedrich I, Schoeppe W, Bereiter-Hahn J:
Influence of cytokines and uremic sera on the contractility of cultured cardiac myocytes
Abstracts of the University of California San Diego (UCSD) Asilomar Conference on "The
molecular and cellular biology of the cardiac myocyte" 17.-20.11.1991, Monterey/USA: 92: 1991
19. Weisensee D, Löw-Friedrich I, Seeger T, Schoeppe W, Bereiter-Hahn J:
Cocultures of fetal and adult cardiomyocytes yield to rhythmically beating rod shaped heart cells
from adult rat
Eur. J. Cell Biol. 57 (36): 243: 1992
20. Koch B, Löw-Friedrich I, Sharma H, Weisensee D, Schoeppe W:
Detection of "heat shock proteins" (hsps) differs considerably with respect to the assessment
procedure employed
Eur. J. Cell Biol. 60 (37): 308: 1993
21. Domljan Z, Popovic M., Mladenovic V, Rozman B, Mihailovic D, Jajic I, Zivkovic M, Strand V, Löw-
Friedrich I, Oed Ch, Musikic P, Seifert H:
Efficacy and safety of leflunomide in the treatment of patients with rheumatoid arthritis (RA)
Scientific program of the American College of Rheumatology 57th Annual Scientific Meeting, San
Antonio, Texas, November 1993
22. Sharma H S, Weisensee D, Löw-Friedrich I, Schoeppe W, Schaper W:
Vascular endothelial growth factor expression in cardiac myocytes in vitro and its upregulation by
tumor necrosis factor-alpha
J. Cell Biochem. 216: 17D: 1993
23. Vescia M, Löw-Friedrich I, Ernst W, Schoeppe W:
Echographische Bestimmung des Hydratationszustandes bei nierentransplantierten Patienten
(NTP)
Nieren- und Hochdruckkrankheiten 22 (10): 309: 1993
24. Mühler M, Schoeppe W, Löw-Friedrich I:
An immunoassay for the detection of the 72-kD heat shock protein (HSP72) in cultured human
hepatoma cells as a parameter of hepatocellular drug toxicity
Naunyn-Schmiedeberg's Arch. Pharmacol. 348: 69: 1993

25. Schoeppe W, Weisensee D, Koch B, Löw-Friedrich I:
Effects of compounds accumulating during chronic renal failure on cardiac myocyte function
Abstracts of the "1st European Kidney Research Forum" (EKRF), Kloster Banz,
Erlangen/Nürnberg, P128, April 1994
Kidney Int. 47 (2): p684: 1995

26. Rozman B, Domljan Z, Popovic M, Mladenovic V, Mihajlovic D, Jajic J, Zivkovic M, Löw-Friedrich I, Oed Ch, Seifert H, Strand V:
Long term administration of leflunomide to patients with rheumatoid arthritis (RA)
Arthritis and Rheumatism 37 (9): 1071: 1994

27. Rozman B, Domljan Z, Popovic M, Mladenovic V, Mihajlovic D, Jajic J, Zivkovic M, Löw-Friedrich I, Oed Ch, Seifert H, Strand V:
Weekly administration of leflunomide to patients with active rheumatoid arthritis (RA)
Arthritis and Rheumatism 37 (9): 1072: 1994

28. Weisensee D, Löw-Friedrich I, Lenz Th, Schoeppe W:
Co-cultures of fetal and adult cardiomyocytes: a new model for the study of adult myocytes with sustained intrinsic rhythmic activity
Abstracts of the 18th Congress of the German League for the Fight against Hypertension, joint meeting with the Dutch Hypertension Society, Münster, November 1994

29. Schoeppe W, Löw-Friedrich I, Weisensee D:
Changes in contractility patterns of cardiac myocytes after incubation with uremia specific molecules in vitro
Blood Purif. 15 (2): P16: 1997

30. Smolen J S, Kalden J R, Rozman B, Scott D L, Rosenberg R, Löw-Friedrich I for the European Leflunomide Study Group:
Efficacy and safety of leflunomide versus placebo and sulfasalazine in rheumatoid arthritis: a double-blind, randomized, pivotal trial
Rheumatology in Europe 27 (2): 155: 1998

31. Kalden J R, Williams B D, Kvien T K, Rosenberg R, Löw-Friedrich I for the European Leflunomide Study Group:
Rapid onset of action of leflunomide, a novel immunomodulatory agent for rheumatoid arthritis
Rheumatology in Europe 27 (2): 157: 1998

32. Metzler C, Löw-Friedrich I, Reinhold-Keller E, Schmitt W H, Gross W L:
Leflunomide, a new, promising agent in maintenance of remission in Wegener's granulomatosis (WG)
Clin. Exp. Immunol. 112 (1): 154 (O): 1998

33. Scott D L, Schattenkirchner M, Smolen J S, Kalden J R, Rozman B, Löw-Friedrich I, Rosenberg R for the European Leflunomide Study Group:
Efficacy of leflunomide vs. placebo vs. sulfasalazine in rheumatoid arthritis: effect of disease duration
Arthritis and Rheumatism 41 (9): 735: 1998

Text books:

1. Löw I:
Mögliche Komplikationen der therapeutischen Lokalanästhesie
In: Gross D, Hrsg., Therapeutische Lokalanästhesie, Band II: Anwendung in Klinik und Praxis,
Stuttgart, Hippokrates Verlag 1988, pp 50-55
2. Löw-Friedrich I, Schoeppe W:
Transplantation: Grundlagen, Klinik, Ethik und Recht
Darmstadt, Wissenschaftliche Buchgesellschaft, 202 Seiten, 1996

Review Articels:

1. Löw-Friedrich I, Schoeppe W:
Zellkulturmodelle in der Diagnostik
Forschung Frankfurt 8 (1): 38-47, 1990
2. Löw-Friedrich I, von Bredow F, Schoeppe W:
Eine biochemische Methode zur Überprüfung der herzscheidigenden Wirkung von Zytostatika
Der Kassenarzt 21: 42-44, 1991
3. Löw-Friedrich I, Schoeppe W:
"Stress-Proteine" als Grundlage eines Testverfahrens zur Erkenntnis zellschädigender Einflüsse
Alternativen zu Tierexperimenten (ALTEX) 15: 5-17, 1991
4. Grützmaclier P, Scheuermann E, Löw I, Bergmann M, Rauber K, Baum R, Heuser J, Schoeppe W:
Correction of renal anemia by recombinant human erythropoietin: effect on myocardial function
Contr. Nephrol. 66: 176-184, 1988
5. Löw-Friedrich I, Schoeppe W:
"Stress-Proteine" signalisieren Gefahr
In-vitro-Systeme 7 (4): 5-6, 1992

Book Chapters:

1. Weisensee D, Löw-Friedrich I, Schoeppe W, Bereiter-Hahn J:
Effects of uremic compounds on cultured myocytes: a model for uremic myocardial pathology
In: Bernd A, Bereiter-Hahn J, Hevert F, Holzmann H, Eds., Cell and tissue culture models in dermatological research, Berlin/Heidelberg, Springer 1993, pp 67-74
2. Löw-Friedrich I, Weisensee D, Mitrou P, Schoeppe W:
The synthesis of stress proteins in cultured cardiac myocytes is induced by the interleukins and tumor necrosis factor
In: Faist, Meakins, Schildberg, Eds., Host defense dysfunction in trauma, shock and sepsis, Berlin/Heidelberg, Springer 1993, pp 677-679
3. Löw-Friedrich I, Weisensee D, Mitrou P S, Bereiter-Hahn J, Schoeppe W:
Cytokines directly affect contractility and stress protein formation of cardiac myocytes
In: Bergmann L, Mitrou P S, Eds., Cytokines in cancer therapy, in: Huber H, Queisser W, Eds., Contributions to oncology, Basel, Karger 1994, vol. 46, pp 368-373
4. Weisensee D, Schnaars Y, Schoeppe W, Löw-Friedrich I:
Changes in energy metabolism of cardiac myocytes after incubation with potential uremic toxins in vitro
In: Timio M, Wizemann V, Venanzi S, Eds., Cardioneurology 3, Assisi, Editoriale Bios 1995